CA2903229A1 - Manufacture of peanut formulations for oral desensitization - Google Patents

Manufacture of peanut formulations for oral desensitization Download PDF

Info

Publication number
CA2903229A1
CA2903229A1 CA2903229A CA2903229A CA2903229A1 CA 2903229 A1 CA2903229 A1 CA 2903229A1 CA 2903229 A CA2903229 A CA 2903229A CA 2903229 A CA2903229 A CA 2903229A CA 2903229 A1 CA2903229 A1 CA 2903229A1
Authority
CA
Canada
Prior art keywords
ara
peanut
glidant
capsule
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2903229A
Other languages
English (en)
French (fr)
Inventor
Bryan Walser
Howard V. Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Aimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2903229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics Inc filed Critical Aimmune Therapeutics Inc
Publication of CA2903229A1 publication Critical patent/CA2903229A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2903229A 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization Pending CA2903229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
US61/784,964 2013-03-14
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (1)

Publication Number Publication Date
CA2903229A1 true CA2903229A1 (en) 2014-10-02

Family

ID=51528061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903229A Pending CA2903229A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Country Status (19)

Country Link
US (5) US9198869B2 (https=)
EP (3) EP2968529B1 (https=)
JP (3) JP6752140B2 (https=)
CN (2) CN105101994B (https=)
AU (5) AU2014240404B2 (https=)
BR (1) BR112015021756B1 (https=)
CA (1) CA2903229A1 (https=)
DK (2) DK3482771T3 (https=)
ES (2) ES2940686T3 (https=)
FI (2) FI3482771T3 (https=)
FR (1) FR23C1026I2 (https=)
HU (1) HUE051831T2 (https=)
MX (1) MX2015010315A (https=)
NL (1) NL301236I2 (https=)
NO (1) NO2023027I1 (https=)
PL (1) PL2968529T3 (https=)
PT (1) PT2968529T (https=)
SI (1) SI2968529T1 (https=)
WO (1) WO2014159607A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2014159607A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
MA41558B1 (fr) 2015-02-20 2023-02-28 Univ Leland Stanford Junior Compositions d'allergènes mélangés et leurs procédés d'utilisation
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂ａ及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
KR102609841B1 (ko) * 2016-12-05 2023-12-06 리액타 바이오테크 리미티드 경구 식품 유발시험 식사 제제
EP3568027A4 (en) * 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY
AU2017279647B2 (en) 2017-02-15 2022-05-26 Euroimmun Medizinische Labordiagnostika Ag An improved assay for the diagnosis of peanut allergy
NZ760884A (en) 2017-07-18 2023-05-26 Nestle Sa Methods for making mixed allergen compositions
JP7498661B2 (ja) 2017-11-02 2024-06-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法の方法
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
CA3087792A1 (en) 2018-01-16 2019-07-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment and prevention of seed allergies
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
JP7659494B2 (ja) * 2018-12-17 2025-04-09 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 卵に対する経口免疫療法のための製剤、製造方法、及び卵アレルギーの治療
CA3123605A1 (en) * 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CN113507844A (zh) 2019-01-23 2021-10-15 前品牌股份有限公司 制备混合型过敏原组合物的方法
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
ES3038192T3 (en) * 2019-08-08 2025-10-10 Evonik Operations Gmbh Method of preparing a solid dosage form and a lubricant
BR112022009664A2 (pt) * 2019-11-20 2022-08-16 Nestle Sa Métodos e sistemas para gerenciamento de distribuição e tratamento de um fármaco oral de imunoterapia para alergia a alimentos
CA3162040A1 (en) * 2019-12-23 2021-07-01 Bronwyn POLLOCK Pharmaceutical compositions
BR112022026945A2 (pt) 2020-07-01 2023-03-07 Nestle Sa Determinação de equipe médica para imunoterapia oral
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CN119365211A (zh) 2022-04-11 2025-01-24 爱尔开-阿贝优公司 花生过敏原组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) * 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
WO2001039799A2 (en) 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Passive desensitization
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
MXPA05009079A (es) * 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
CN101351191A (zh) * 2005-12-28 2009-01-21 特瓦制药工业有限公司 生物利用率改善的非诺贝特药物制剂
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
JP2012509329A (ja) 2008-11-19 2012-04-19 アバントール パフォーマンス マテリアルズ， インコーポレイテッド 直接圧縮可能で高機能性な顆粒状の微結晶性セルロースベース賦形剤、それらの製造プロセスおよび使用
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
GB201104537D0 (en) 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
ES2936312T3 (es) * 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013087119A1 (en) * 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
WO2014159607A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
US9492535B2 (en) * 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP3568027A4 (en) 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY
JP7498661B2 (ja) 2017-11-02 2024-06-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法の方法

Also Published As

Publication number Publication date
AU2016231523A1 (en) 2016-10-06
CN109125283A (zh) 2019-01-04
US9198869B2 (en) 2015-12-01
CN105101994A (zh) 2015-11-25
SI2968529T1 (sl) 2021-03-31
JP6891205B2 (ja) 2021-06-18
JP2019108357A (ja) 2019-07-04
BR112015021756A2 (pt) 2017-07-18
AU2020202685B2 (en) 2022-01-20
EP2968529B1 (en) 2020-08-05
AU2020202685A1 (en) 2020-05-14
AU2022201858B2 (en) 2024-04-04
AU2016231523B2 (en) 2018-05-31
DK2968529T3 (da) 2020-10-12
DK3482771T3 (da) 2023-03-20
EP3482771B1 (en) 2023-01-18
PL2968529T3 (pl) 2021-04-19
JP7454519B2 (ja) 2024-03-22
CN105101994B (zh) 2018-10-12
NO2023027I1 (no) 2023-07-06
BR112015021756A8 (pt) 2019-11-19
US20140271836A1 (en) 2014-09-18
US20200129378A1 (en) 2020-04-30
FI3482771T3 (fi) 2023-04-03
EP3482771A1 (en) 2019-05-15
MX2015010315A (es) 2016-04-13
US10449118B2 (en) 2019-10-22
AU2022201858A1 (en) 2022-04-07
BR112015021756B1 (pt) 2023-01-10
US11141352B2 (en) 2021-10-12
US20160030289A1 (en) 2016-02-04
AU2014240404B2 (en) 2016-07-21
JP2021073321A (ja) 2021-05-13
JP6752140B2 (ja) 2020-09-09
JP2016512537A (ja) 2016-04-28
FR23C1026I2 (fr) 2024-07-26
ES2826224T3 (es) 2021-05-17
HUE051831T2 (hu) 2021-03-29
HK1217660A1 (zh) 2017-01-20
EP3998080A1 (en) 2022-05-18
WO2014159607A1 (en) 2014-10-02
FR23C1026I1 (fr) 2023-10-06
FIC20230022I1 (fi) 2023-07-04
US20180042816A1 (en) 2018-02-15
PT2968529T (pt) 2020-11-10
EP2968529A1 (en) 2016-01-20
AU2014240404A1 (en) 2015-09-17
NL301236I2 (nl) 2025-07-31
US20230120350A1 (en) 2023-04-20
ES2940686T3 (es) 2023-05-10
EP2968529A4 (en) 2016-10-05
AU2018222980A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
AU2022201858B2 (en) Manufacture of peanut formulations for oral desensitization
US20230139230A1 (en) Egg protein formulations and methods of manufacture thereof
WO2014159609A1 (en) Peanut formulations and uses thereof
HK40008413A (en) Manufacture of peanut formulations for oral desensitization
HK40008413B (en) Manufacture of peanut formulations for oral desensitization
HK40003142A (en) Manufacture of peanut formulations for oral desensitization
HK1217660B (zh) 用於口服脱敏的花生制剂的制备

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250514

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250514